Table 2.
Clinicopathological parameters related to death
| Parameter | Alive | Dead | p-valuea | |
|---|---|---|---|---|
| Age, mean (yr) | 51.6 ± 12.3 | 53.0 ± 16.0 | .75b | |
| Category | MUC | 19 (100) | 0 | .20 |
| MUMPC | 14 (82.4) | 3 (17.6) | ||
| IMPC | 12 (80.0) | 3 (20.0) | ||
| IDMPC | 10 (76.9) | 3 (23.1) | ||
| MUC vs MUMPC | MUC | 19 (100) | 0 | .06 |
| MUMPC | 14 (82.4) | 3 (17.6) | ||
| NG | Low | 7 (100) | 0 | .34 |
| Intermediate | 29 (87.9) | 4 (12.1) | ||
| High | 19 (79.2) | 5 (20.8) | ||
| Mitosis | Low | 31 (93.9) | 2 (6.1) | .14 |
| Intermediate | 8 (72.7) | 3 (27.3) | ||
| High | 16 (80.0) | 4 (20.0) | ||
| ER | Negative | 6 (66.7) | 3 (33.3) | .07 |
| Positive | 49 (89.1) | 6 (10.9) | ||
| PR | Negative | 9 (64.3) | 5 (35.7) | .01 |
| Positive | 46 (92.0) | 4 (8.0) | ||
| HER2 | Negative | 47 (92.2) | 4 (7.8) | .01 |
| Positive | 8 (61.5) | 5 (38.5) | ||
| Ki-67 | Low | 19 (95.0) | 1 (5.0) | .16 |
| High | 36 (81.8) | 8 (18.2) | ||
| MS | LA | 20 (82.9) | 0 | .05 |
| LB | 29 (82.9) | 6 (17.1) | ||
| HER2 | 2 (50.0) | 2 (50.0) | ||
| Basal-like | 4 (80.0) | 1 (20.0) | ||
| T-stage | 1 | 27 (100) | 0 | < .01 |
| 2 | 24 (88.9) | 3 (11.1) | ||
| 3 | 4 (40.0) | 6 (60.0) | ||
| LNM | Absence | 36 (97.3) | 1 (2.7) | < .01 |
| Presence | 19 (70.4) | 8 (29.6) |
MUC, mucinous carcinoma without micropapillary feature; MUMPC, mucinous carcinoma with micropapillary feature; IMPC, invasive micropapillary carcinoma; IDMPC, mixed invasive ductal and micropapillary carcinoma; NG, nuclear grade; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; MS, molecular subtype; LA, luminal A; LB, luminal B; LNM, lymph node metastasis.
a
Chi-square test;
b
t test (2-tailed).